THE WOODLANDS, Texas,
May 10, 2016 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today
announced that Praveen Tyle, Ph.D.
will join the company as its executive vice president of research
and development, effective May 16,
2016, and will report to Lonnel
Coats, Lexicon's president and chief executive officer.
Dr. Tyle recently served as president, chief executive
officer and board member of Osmotica Holdings and Osmotica
Pharmaceutical.
Dr. Tyle joins Lexicon with more than 30 years of pharmaceutical
industry experience of advancing new medical device and drug
candidate pipelines to commercial success. Dr. Tyle led and
completed the successful merger of Vertical Pharmaceuticals and
Trigen Laboratories with Osmotica Holdings in February 2016.
Dr. Tyle joined Osmotica as chief scientific officer and executive
vice president in August 2012 before
his promotion to president and chief executive officer in January
2013.
Prior to Osmotica, Dr. Tyle's experience included service as
executive vice president and chief science officer for the United
States Pharmacopeia; senior vice president and global head of
research and development & business development and licensing
at Novartis OTC; corporate senior vice president of global research
and development and chief scientific officer at Bausch + Lomb; and
vice president and global head of pharmaceutical sciences at
Pharmacia until its acquisition by Pfizer.
"We are pleased to have Praveen join Lexicon as our new head of
research and development," said Lonnel
Coats. "He will be instrumental in developing and
progressing Lexicon's rich pipeline forward so that patients may
benefit from continued treatment innovations for years to
come."
Dr. Tyle earned his doctorate in pharmaceutics and
pharmaceutical chemistry from the Ohio State
University and his bachelor of pharmacy (honors) degree at
the Indian Institute of Technology,
Banaras Hindu University in India.
He sits on a number of boards of directors and advisory
committees including those at EyeGate Pharmaceuticals, Inc.; Orient
Europharma, Inc.; GrayBug, LLC; and Yolia Health. Dr. Tyle
has over 20 issued patents and over 130 scientific publications and
presentations to his credit and has served as editor for seven
books on drug development.
"I am looking forward to joining the Lexicon team, with the
primary goal of developing the full commercial potential of the
insightful science they have built," said Praveen Tyle, Ph.D. "Telotristat etiprate and
sotagliflozin represent the beginning of what I believe will become
a diverse and extensive long-term pipeline, built from Lexicon's
in-house novel targets and potentially augmented by complementary
in-licensed opportunities."
About Lexicon
Lexicon is a fully integrated biopharmaceutical company that is
applying a unique approach to gene science based on Nobel
Prize-winning technology to discover and develop precise medicines
for patients with serious, chronic conditions. Through its
Genome5000™ program, Lexicon scientists have studied the role and
function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. Lexicon has a pipeline of promising drug candidates
in clinical and pre-clinical development in oncology, diabetes and
metabolism. For additional information please visit.
www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to Lexicon's ability
to meet its capital requirements, successfully conduct preclinical
and clinical development of its drug candidates, obtain necessary
regulatory approvals, achieve its operational objectives, obtain
patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2015, as filed
with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/praveen-tyle-phd-joins-lexicon-as-executive-vice-president-of-research-and-development-300265395.html
SOURCE Lexicon Pharmaceuticals, Inc.